Patents Assigned to Mereo BioPharma 2 Limited
  • Publication number: 20190192485
    Abstract: This invention relates to a dosage regimen comprising 4,4?-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile and a combined oral contraceptive for use in the treatment of endometriosis in a non-pregnant, pre-menopausal female. The invention also relates to a multi-phase combination preparation comprising 4,4?-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile and a combined oral contraceptive. The invention also relates to a kit comprising said multi-phase preparation and instructions for use.
    Type: Application
    Filed: August 21, 2017
    Publication date: June 27, 2019
    Applicant: MEREO BIOPHARMA 2 LIMITED
    Inventors: Jackie PARKIN, Lloyd B. KLICKSTEIN
  • Patent number: 10064844
    Abstract: The present invention relates to low-dose pharmaceutical compositions comprising the aromatase inhibitor 4,4?-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile, as the active ingredient in a suitable carrier. The present invention also relates to a process for their preparation and to their use as medicaments.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: September 4, 2018
    Assignee: MEREO BIOPHARMA 2 LIMITED
    Inventors: Ann Taylor, Lloyd B. Klickstein, Jeewan Thakur
  • Patent number: 9750724
    Abstract: The aromatase inhibitor 4,4?-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile increases testosterone levels and treats hypogonadism and related diseases. A particular dosing regimen is disclosed as well as pharmaceutical compositions comprising said of 4,4?-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile, optionally in combination with other active ingredients and kits comprising the pharmaceutical compositions.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: September 5, 2017
    Assignee: Mereo BioPharma 2 Limited
    Inventors: Ann Taylor, Lloyd B. Klickstein
  • Publication number: 20160346257
    Abstract: The present invention relates to low-dose pharmaceutical compositions comprising the aromatase inhibitor 4,4?-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile, as the active ingredient in a suitable carrier. The present invention also relates to a process for their preparation and to their use as medicaments.
    Type: Application
    Filed: May 27, 2016
    Publication date: December 1, 2016
    Applicant: MEREO BIOPHARMA 2 LIMITED
    Inventors: Ann TAYLOR, Lloyd B. KLICKSTEIN, Jeewan THAKUR
  • Publication number: 20160243084
    Abstract: The aromatase inhibitor 4,4?-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile increases testosterone levels and treats hypogonadism and related diseases. A particular dosing regimen is disclosed as well as pharmaceutical compositions comprising said of 4,4?-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile, optionally in combination with other active ingredients and kits comprising the pharmaceutical compositions.
    Type: Application
    Filed: February 22, 2016
    Publication date: August 25, 2016
    Applicant: Mereo BioPharma 2 Limited
    Inventors: Ann Taylor, Lloyd B. Klickstein
  • Patent number: 9370505
    Abstract: The invention relates to low-dose pharmaceutical compositions comprising the aromatase inhibitor 4,4?-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile, as the active ingredient in a suitable carrier. The present invention also relates to a process for their preparation and to their use as therapeutic agents.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: June 21, 2016
    Assignee: Mereo BioPharma 2 Limited
    Inventors: Ann Taylor, Lloyd B. Klickstein, Jeewan Thakur